SLAM family member 8Genealiases: BLAME · CD353 · SBBI42
Q-omics provides the consensus-scored SLAMF8 profile across patient tissues and cancer cell-line models. SLAMF8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SLAMF8 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, SLAMF8 RNA expression shows 21,099 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where SLAMF8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLAMF8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLAMF8 survival associations across molecular data types. SLAMF8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLAMF8 RNA expression–survival associations across cancer types. High SLAMF8 expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, CESC, HNSC and LUAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SLAMF8 RNA expression.
This table summarizes SLAMF8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SLAMF8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLAMF8 shows higher tumor expression in KIRC, HNSC, KIRP, STAD, LIHC and BLCA. The KIRC box plot shows higher SLAMF8 RNA expression in tumor versus normal tissue (log2 FC = +2.876, t-test p < 0.001).
This table shows molecular features associated with SLAMF8 in patient tissues and cancer cell lines. In patient samples, SLAMF8 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLAMF8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
